BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

World

Differentia Bio Reports Clinical Support for AI-Predicted Treatment Strategies in IgG4-Related Disease

From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharma...

November 05, 2026 | News

Zuellig Pharma Acquires Hangzhou Facility to Strengthen Clinical Trial Supply in China

The acquisition of our newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across Chi...

November 05, 2026 | News

Minghui Signs Japan Licensing Deal With ASKA Worth Up to $440 Million for Thyroid Eye Disease Therapy

Minghui Pharmaceutical ("Minghui") and ASKA Pharmaceutical Co., Ltd. ("ASKA") announced that they have entered into an exclusive license agreement fo...

November 05, 2026 | News

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

November 04, 2026 | Analysis

Lonza to Acquire Five US CDMO Sites from Merck KGaA to Double Manufacturing Footprint

Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US footprint to nine CDMO sites wit...

November 04, 2026 | News

InventisBio’s Nomelcitinib Achieves Over 70% PASI 90 Response in Phase III Psoriasis Trial

InventisBio Co., Ltd. announced that its JH2 selective TYK2 inhibitor nomelcitinib (D-2570) has met both the primary endpoint and the key s...

November 04, 2026 | News

Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial

Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...

November 02, 2026 | News

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 02, 2026 | News

Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...

October 30, 2026 | News

Enveda and Anthropic Cut Drug Batch Review Time by 89% Using Claude AI

In an internal evaluation, Claude-powered workflows reduced batch-record review time by 89% and produced a first draft of regulatory content in hours rat...

October 29, 2026 | News

Octant Secures FDA Orphan Drug Designation for OCT-980 to Treat Retinitis Pigmentosa

Octant, Inc. (“Octant”), a clinical-stage drug discovery company developing correctors for protein misfolding diseases, announced that th...

October 29, 2026 | News

Menarini and Georgiamune Strike $1.1 Billion Licensing Deal to Advance Next-Generation Cancer Immunotherapy

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to...

October 27, 2026 | News

Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth

Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and U.S. manufacturing operations contribute to earn...

October 23, 2026 | Company results

Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation

Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeut...

October 22, 2026 | News

Stay Connected